GWPH News and Press, GW Pharmaceuticals Plc From 03/24/21

There has been a surge of mergers and acquisitions activity in the cannabis industry of late. Aphria (NASDAQ: APHA) and Tilray (NASDAQ: TLRY) are linking up in one of the sector's highest-profile mergers, and other industries are getting in on the action. Jazz Pharmaceutic...

The ETF tracks the largest and most promising Cannabis companies in North America, diversifying risk to investors. The Cannabis market is ever-growing as more countries and U.S. states are legalizing recreational use. While valuations of included companies are high, they are nowhe...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 9, 2021 – The mental health treatment space is heading into a period of incredible innovation. New therapies and unconventional pharmaceuticals are receiving serious attention ...

Shares of GW Pharmaceuticals (NASDAQ: GWPH) rose 40.5% in February, according to data provided by S&P Global Market Intelligence . The bulk of the move came on Feb. 3 when Jazz Pharmaceuticals (NASDAQ: JAZZ) announced it would be purchasing GW for $7.2 billion, or th...

With 1 in 3 Americans now living in a state where adult pot use is legal, Virginia is no longer sitting on the sidelines. Over the weekend, local lawmakers narrowly approved compromise legislation that would make it the first state in the south to allow recreational marijuana. The bill now go...

GW Pharmaceuticals (GWPH) announced that the European Medicines Agency has issued a positive opinion on its Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex.The decision by the EMA’s Commit...

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion on GW Pharmaceuticals' (GWPH) Type II variation application for Epidyolex (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex ((TSC)), for patients two ye...

LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the Eur...

Jazz Pharmaceuticals (JAZZ) reported Q4 EPS that missed analyst estimates by $0.20, though revenue beat by nearly $26.7M.Product sales of Xywav, a nacrolepsy drug that launched in November, in the quarter were $15.3M.At the end of Q4, there were 1,900 patients on Xywav, which has 92% les...

The trading week was a little shorter as markets celebrated President day on Monday. However, there was still big news this week. Verano Holdings began trading on the CSE this week using the symbol VRNO after closing the reverse takeover of Alternative Medi...